Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review

被引：7

作者：

Tsigkas, Grigorios ^{[1
]}

Vakka, Angeliki ^{[1
]}

Apostolos, Anastasios ^{[1
,2
]}

Bousoula, Eleni ^{[3
]}

Vythoulkas-Biotis, Nikolaos ^{[1
]}

Koufou, Eleni-Evangelia ^{[1
]}

Vasilagkos, Georgios ^{[1
]}

Tsiafoutis, Ioannis ^{[4
]}

Hamilos, Michalis ^{[5
]}

Aminian, Adel ^{[6
]}

Davlouros, Periklis ^{[1
]}

机构：

[1] Univ Hosp Patras, Dept Cardiol, Patras 26504, Greece

[2] Natl & Kapodistrian Univ Athens, Hippocrat Gen Hosp, Dept Cardiol 1, Athens 15772, Greece

[3] Tzaneio Gen Hosp, Dept Cardiol, Piraeus 18536, Greece

[4] Red Cross Hosp, Dept Cardiol 1, Athens 11526, Greece

[5] Heraklion Univ Hosp, Dept Cardiol, Iraklion 71500, Crete, Greece

[6] Ctr Hospitalier Univ Charleroi, Dept Cardiol, B-6042 Charleroi, Belgium

来源：

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE | 2023年 / 10卷 / 04期

关键词：

cancer; acute coronary syndrome (ACS); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); triple antithrombotic therapy (TAT); atrial fibrillation (AF); cardiotoxicity; PERCUTANEOUS CORONARY INTERVENTION; PATENT FORAMEN OVALE; ANTITHROMBOTIC THERAPY; ANTICOAGULANT TREATMENT; ATRIAL-FIBRILLATION; OUTCOMES; DISEASE; CLOSURE; STROKE; BREAST;

D O I：

10.3390/jcdd10040135

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

引用

页数：16

共 50 条

[41] Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy
Huang, Jiaming
Liao, Foqiang
Tang, Jianhua
Shu, Xu
CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 231
[42] Dual Antiplatelet Therapy And Heparin "Bridging" Significantly Increase The Risk Of Bleeding At Device Implantation
Tompkins, Christine
Cheng, Alan
Dalal, Darshan
Brinker, Jeffrey A.
Leng, Charles T.
Marine, Joseph E.
Nazarian, Saman
Spragg, David D.
Sinha, Sunil
Halperin, Henry
Tomaselli, Gordon F.
Berger, Ronald D.
Calkins, Hugh
Henrikson, Charles A.
CIRCULATION, 2008, 118 (18) : S596 - S596
[43] Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes
Alfredsson, Joakim
Neely, Benjamin
Neely, Megan L.
Bhatt, Deepak L.
Goodman, Shaun G.
Tricoci, Pierluigi
Mahaffey, Kenneth W.
Cornel, Jan H.
White, Harvey D.
Fox, Keith A. A.
Prabhakaran, Dorairaj
Winters, Kenneth J.
Armstrong, Paul W.
Ohman, E. Magnus
Roe, Matthew T.
HEART, 2017, 103 (15) : 1168 - 1176
[44] The risk of bleeding on dual antiplatelet therapy after drug-eluting stent implantation
Latib, Azeem
Morici, Nuccia
Cosgrave, John
Qasim, Asif
Airoldi, Flavio
Brambilla, Nedy
Bonizzoni, Ermino
Godino, Cosmo
Rogacka, Renata
Tavano, Device
Romagnoli, Enrico
Magni, Valerie
Cheffo, Alaide
Montorfano, Matteo
Aranzulla, Tiziana C.
Bedogni, Francesco
Castelli, Alfredo
Briguori, Carlo
Colombo, Antonio
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : B87 - B87
[45] Antiplatelet therapy and risk of bleeding in hemodialysis patients
Perales, MCS
Vázquez, E
Cortés, MJG
Borrego, FJ
Borrego, J
del Barrio, PP
Liébana, A
Gil, JM
Viedma, G
Bañasco, VP
NEFROLOGIA, 2002, 22 (05): : 456 - 462
[46] High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment
Atay, Kadri
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (09) : 980 - 981
[47] Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk A Cost Consequence Simulation From PARIS
Baber, Usman
Leisman, Daniel E.
Cohen, David J.
Gibson, C. Michael
Henry, Timothy D.
Dangas, George
Moliterno, David
Kini, Annapoorna
Krucoff, Mitchell
Colombo, Antonio
Chieffo, Alaide
Sartori, Samantha
Witzenbichler, Bernhard
Steg, Philippe Gabriel
Pocock, Stuart J.
Mehran, Roxana
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (01): : e004945
[48] Mortality risk with dual antiplatelet therapy?
Sethi, Ankur
Arora, Rohit
LANCET, 2015, 386 (10003): : 1534 - 1535
[49] Benefit-Risk Profile of Extended Dual Antiplatelet Therapy Beyond 1 Year in Patients With High Risk of Ischemic or Bleeding Events After PCI
Wang, Hao-Yu
Gao, Run-Lin
Yin, Dong
Xu, Bo
Dou, Ke-Fei
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (17) : B26 - B26
[50] Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI
Wang, Hao-Yu
Gao, Run-Lin
Xu, Bo
Yang, Yue-Jin
Yin, Dong
Wang, Yang
Dou, Ke-Fei
PLATELETS, 2021, 32 (04) : 533 - 541

← 1 2 3 4 5 →